Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fresenius SE & Co KGaA (OTCQX International Premier:FSNUY)

Delayed Data
As of Feb 12
 -0.14 / -0.93%
Today’s Change
Today|||52-Week Range
Health Services
Medical/Nursing Services

Company Description

Fresenius SE & Co. KGaA engages in the provision of healthcare related products and services. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment provides dialysis products and services for patients with chronic kidney failure. The Fresenius Kabi segment offers IV drugs including intravenously administered generic anesthetics, anti-infectives, analgesics, and drugs for the treatment of oncological and other critical diseases and infusion solutions and blood volume substitutes for infusion therapy. The Fresenius Helios segment operates hospitals. The Fresenius Vamed segment manages projects and provides services for hospitals and other healthcare facilities. The Corporate and Other segment comprises the holding activities of the company and the activities of the information technology service provider Fresenius Netcare. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Contact Information

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
Bad Homburg Hessen 61352
Investor Relations:



Other institutional0.10%
Mutual fund holders0.00%
Individual stakeholders--

Top Executives

Ulf Mark SchneiderChairman-Management Board, President & CEO
Stephan SturmChief Financial Officer
Jürgen GötzChief Legal & Compliance Officer
Daniela HegemannManager-Events
Francesco de MeoMember-Management Board